PsiOxus Therapeutics has a highly experienced management team.
Chief Executive Officer: Dr John Beadle
Dr John Beadle was Entrepreneur in Residence at Imperial College London, where he helped to establish Myotec Therapeutics as a spin-out business. He became CEO of Myotec in late 2008, rapidly securing seed financing followed by a £5.6 million series A funding round from Imperial Innovations and Invesco Perpetual in early 2010. During this time, John was also Executive Chairman and CEO of Hybrid Biosystems, securing further seed financing for this Oxford based start-up. In 2010, John's leadership of these two private companies led to their combination to form PsiOxus Therapeutics Ltd. John was previously the co-founder of the vaccine company PowderMed. In 2004 he helped to raise £20 million from leading UK and US Venture Capital Funds and was then Chief Medical Officer and board director leading to the trade sale of PowderMed to Pfizer for over US$300 million in 2006. John has previously held roles at PowderJect, Pfizer and Glaxo SmithKline where he was most recently VP of Global Medical Operations. John was trained in Medicine at the University of Witwatersrand and received his MBA with distinction from the London Business School.
Chief Financial Officer and Company Secretary: Theodora Harold
Theodora Harold is a chartered accountant with significant experience as a Chief Financal Officer and Company Secretary with early stage and growing companies in the biotech sector. She has a background in both industry and corporate finance with 16 years of experience in SMEs in the biotech and hi-tech sectors and has held roles with Cytomyx Holdings plc, RioTech Pharmaceuticals Ltd, OrthoMimetics Ltd, Hybrid Biosystems Ltd, Myotec Therapeutics Ltd and Mission Therapeutics Ltd. Prior to this, Theodora trained with PricewaterhouseCoopers and read Classics at Trinity College, Cambridge.
Chief Scientific Officer: Dr Kerry Fisher
Dr Kerry Fisher is a Scientific Founder of Hybrid Biosystems Ltd. As well as serving on the Board he has held roles as Chief Scientific Officer and CEO. He is a gene delivery specialist working with therapeutic viruses for the treatment of cancer and for vaccination against infectious disease. His areas of interest include pharmacology and medicinal virology, with a particular interest in the modification of viruses for clinical use. Kerry achieved a 1st class undergraduate degree from the University of Aberdeen and completed his PhD in 2001 at the University of Birmingham. Since graduating Kerry has published over 40 articles and won several awards for his work. As well as his role as Chief Scientific Officer at PsiOxus Therapeutics, Kerry also holds an academic position as Lecturer at the University of Oxford.
Chief Operating Officer: Priya Mande
Priya Mande has over 20 years of experience in the pharmaceutical and biotech sector. She was previously at PowderMed responsible for vaccine immunotherapeutic projects, collaboration with academic institutions and Joint Ventures with other Pharma companies targeting influenza, chronic viral diseases and cancer. Priya was also the Vaccine Research Project Leader for Influenza at Pfizer before becoming COO of Hybrid BioSystems in 2009. She has previously held various roles within Glaxo Wellcome and Glaxo SmithKline over a 12 year period where she was most recently senior Director of R&D Business Projects. Priya studied Biochemistry at Brunel University, received a MBA with distinction from the London Business School and has a Diploma in Company Direction from the Institute of Directors. Priya has received several awards for project leadership including an international collaboration award at the 26th US Army Science Conference.
VP of Pharmaceutical Development: Dr Jeetendra Bhatia
Jeetendra Bhatia has over 15 years of experience in pharmaceutical development & manufacturer. His areas of interest include development of novel therapeutics, GMP manufacture and formulation. Jeetendra has developed both recombinant and microbial vaccines for the treatment of cancer and other infectious disease and has published scientific articles. Jeetendra completed his PhD in 1999 at the University of London, whilst working for the Cancer Research UK, Department of Oncology at The Royal Free Hospital, London. Whilst at the Royal Free Hospital, Jeetendra set up a GMP facility which manufactured a cancer therapeutic used for a Phase I/II clinical trial. The facility was later ISO9001 certified by the MHRA. He has previously held roles as Senior Development Manager at Avidex Ltd and Emergent BioSolutions where he was most recently the Head of Process & Analytical Development before moving to PsiOXus in May, 2011.
Chief Medical Officer: Dr Christine Wilkinson Blanc
Dr Christine Wilkinson Blanc has over 20 years of clinical research and medical affairs experience in the pharmaceutical industry, working in the fields of oncology and haematology. She has collaborated on prominent clinical development programs including docetaxel and irinotecan at Aventis/Rhone-Poulenc Rorer, bevacizumab at Roche and ridaforolimus at Ariad. She also served as Medical Director at GE Healthcare contributing to the development and marketing strategy of diagnostic and functional imaging agents and at Aventis International, where she pioneered the implementation of oncology research programs in Eastern Europe, Latin America and Asia. Most recently Christine operated her own company, consulting to the pharmaceutical and biotechnology industry on a range of oncology programs. Dr Wilkinson Blanc studied Medicine at the Universities of Lyon and Lille. She specialised in Medical Biology, has been Chef de Clinique in Clinical Haematology at Lille University Hospital and also holds a Master of Science in Immunology.
Senior VP of Research and Development: Dr Brian Champion
Dr Champion was previously Executive Director and Head of Immunology for Pfizer's Vaccine Immunotherapeutics Research Unit in La Jolla, California. In this role Brian led the immunology team providing expertise and immunoassays for all Pfizer vaccine projects, including therapeutic T-cell focused vaccines for cancer, antibody focused vaccines for several different diseases as well as several prophylactic infectious disease vaccines. He was also a member of the leadership team as well as Program Lead for an anti-IgE therapeutic vaccine for allergy/asthma. Prior to this role, Brian was Site Head for Pfizer Vaccine Research in the UK. Before joining Pfizer, Dr Champion was Chief Scientific Officer for Lorantis and Celldex, Cambridge, developing protein and DNA-based, antigen-specific immunotherapeutic approaches to a variety of immunological diseases, including therapeutic vaccines and immunotherapeutic biomolecule approaches for cancer, infectious diseases, allergies and autoimmune disorders. Prior to Lorantis, he was with Glaxo and GlaxoWellcome (UK and USA) for 13 years, focusing primarily on target discovery and validation research for autoimmune, allergic and bone disorders.